OLIGONUCLEOTIDE-BASED THERAPIES MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-82291 | Pharmaceutics
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Oligonucleotide-based Therapies Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES MARKET
7.1 GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA OLIGONUCLEOTIDE-BASED THERAPIES MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Biogen
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Akcea Therapeutics
16.3 Bausch & Lomb
16.4 Sarepta Therapeutics
16.5 Kastle therapeutics
16.6 Jazz Pharmaceuticals
16.7 Dynavax Technologies
16.8 Alnylam Pharmaceuticals
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Market by Type :Antisense Oligonucleotide
Aptamer
Other
Market by Application :
Neuromuscular Diseases
Hepatic VOD
Other
Companies
Biogen
Akcea Therapeutics
Bausch & Lomb
Sarepta Therapeutics
Kastle therapeutics
Jazz Pharmaceuticals
Dynavax Technologies
Alnylam Pharmaceuticals
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.